Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3441-3449

  Bonfils, Claire ^a   Kalita, Ann ^a   Dubay, Marja ^a   Siu, Lillian L ^b   Carducci, Michael A ^c   Reid, Gregory ^a   Martell, Robert E ^a   Besterman, Jeffrey M ^a   Li, Zuomei ^a  

^a METHYLGENE INC   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; N (2 AMINOPHENYL) 4 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YLAMINO)METHYL)BENZAMIDE; N-(2-AMINOPHENYL)-4-((4-PYRIDIN-3-YLPYRIMIDIN-2-YLAMINO)METHYL)BENZAMIDE; PYRIMIDINE DERIVATIVE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; DRUG MONITORING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MOUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR XENOGRAFT; ANIMAL; BIOASSAY; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG SCREENING; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BIOLOGICAL ASSAY; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASMS; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50349087906     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4427     Document Type: Article

References (36)

1. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9.
2. Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-78.
3. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007;8:383-93.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
5. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-99.
6. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005;68:917-32.
7. Monneret C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs 2007;18:363-70.
8. Garcia-Manero G, Issa JP. Histone deacetylase inhib itors: a review of their clinical status as antineoplastic agents. Cancer Invest 2005;23:635-42.
9. Marks P. Rifkind RA, Richon VM. Breslow R. Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
10. Gallinari P, Di Marco S, Jones P, Pallaoro M, Stein-kuhler C HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007;17:195-211.
11. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoy-lanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31.
12. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6.
13. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-20.
14. Kato Y, Salumbides BC, Wang XF, et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007;6:70-81.
15. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies Clin Cancer Res 2006;12:4628-35.
16. Qian X, LaRochelle WJ. Ara G, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006;5:2086-95.
17. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-8.
18. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109:2781-90.
19. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 2007;39:1388-405.
20. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma J Clin Oncol 2005;23:3912-22.
21. Moradei O, Leit S, Zhou N, et al. Substituted N-(2-aminophenyl)- benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. Bioorg Med Chem Lett 2006;16:4048-52.
22. Bonfils C, Kalita A, Liu J, Besterman JM, Li Z. Development of whole cell HDAC enzyme assay to analyze inhibitory activity of MGCD0103 in vitro and in vivo. 96th Annual Meeting of the AACR. Proc Am Assoc Cancer Res 2005;46:A606.
23. Li Z, Zhou N, Fournel M, et al. Antitumor activities of MGCD0103, a novel isotype-selective histone deacetylase inhibitor. 16th EORTC-NCI-AACR Symp Mol Targets Cancer Ther. Eur J Cancer Suppl 2004;2:A83.
24. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105:959-67.
25. Vaisburg A. Discovery and development of MGCD0103-an orally active HDAC inhibitor in human clinical trials. XIXth International Symposium on Medicinal Chemistry. Int Symp Med Chem 2006;31 (Suppl. A): Abs L57.
26. +-dependent histone deacetylases. Anal Bio-chem 2003;319:42-8.
27. Heltweg B, Jung M. A microplate reader-based nonisotopic histone deacetylase activity assay. Anal Biochem 2002;302:175-83.
28. Zweidler A. Resolution of histones by poly-acrylamide gel electrophoresis in presence of nonionic detergents. Methods Cell Biol 1978;17:223-33.
29. Dokmanovic M, Perez G, Xu W, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007;6:2525-34.
30. Siu LL, Pili R, Duran I, et al. A phase I study of MGCD0103 given as a three-weekly oral dose in patients with advanced solid tumors. J Clin Oncol 2003;26:1940-7.
31. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. ncogene 2007;26:5541-52.
32. Siu LL, Carducci M, Patterson T, et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as a three-times weekly oral dose in patients (pts) with advanced solid tumors. 18th EORTC-NCI-AACR Cancer Symposium. Eur J Cancer 2006;412:A300.
33. Carducci M, Siu LL, Sullivan R, et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. 2006 ASCO Annual Meeting. Proc Am Soc Clin Oncol 2006;25:A3007.
34. Siu LL, Carducci M, Pearce L, et al. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. AACR-NCI-EORTC Intl Conf Mol Targ Cancer Ther. Clin Cancer Res 2005;11:C77.
35. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000;407:784-8.
36. Garcia-Manero G.Yang AS, Giles F, et al. Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodys-plastic syndrome (MDS) or acute myelogenous leukemia (AML). 48th American Society of Hematology. Blood 2006;108:A1954.